Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023

Hozzl · 2024-03-12T06:14:00Z

Explore the details of Senate Bill 1280 Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Science, Technology, Communications. Stay informed on legislative developments.

3/12/2024, 6:14 AM

Summary of Bill S 1280

Bill 118 s 1280, also known as the Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023, is a piece of legislation introduced in the US Congress. The main purpose of this bill is to address the issue of drug quality and safety by establishing a program for the rapid analysis of narcotics.

The bill proposes the creation of a new office within the Department of Health and Human Services, which will be responsible for conducting rapid analysis of narcotics to ensure their quality and safety. This office will also be tasked with developing new testing methods and technologies to improve the detection of harmful substances in narcotics.

Additionally, the bill includes provisions for increasing funding for research on drug quality and safety, as well as for expanding access to testing and analysis services for law enforcement agencies and other stakeholders. The goal of these measures is to better protect the public from the dangers of contaminated or counterfeit drugs. Overall, the Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023 aims to improve the quality and safety of narcotics through increased testing and analysis, as well as through enhanced research and funding in this area.

Congressional Summary of S 1280

Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023 or the TRANQ Research Act of 2023

This bill requires the National Institute of Standards and Technology (NIST) to support research and other activities related to identifying xylazine (a compound used in veterinary medicine as a nonopioid tranquilizer), novel synthetic opioids, and other new psychoactive substances.

In particular, NIST must support

basic measurement science and research, including graduate and postgraduate research;
near-real time spectrometry capabilities (i.e., a technique for rapidly identifying the chemical composition of a substance);
strategies and voluntary best practices for handling, transporting, and analyzing such substances; and
collaboration with other government agencies, institutions of higher education, and the private sector to enhance relevant narcotic and opioid detection and analysis capabilities.

The Government Accountability Office must evaluate the capability of the federal government to respond to the threats posed by new psychoactive substances like xylazine, including with respect to available technology and laboratories.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1280

Bill S 1280 is currently in the status of Bill Introduced since April 25, 2023. Bill S 1280 was introduced during Congress 118 and was introduced to the Senate on April 25, 2023. Bill S 1280's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 286. as of December 13, 2023

Bipartisan Support of Bill S 1280

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1280

Primary Policy Focus

Science, Technology, Communications

Potential Impact Areas

- Advanced technology and technological innovations

- Chemistry

- Congressional oversight

- Drug trafficking and controlled substances

- Higher education

- Research administration and funding

- Science and engineering education

Alternate Title(s) of Bill S 1280

Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023

TRANQ Research Act of 2023

Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023

A bill to require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.